Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

Inclusion criteria: * A histologically confirmed diagnosis of PTCL * Participants must have relapsed or refractory disease after at least one prior systemic anticancer regimen. Systemic anticancer therapy is defined as chemotherapy or immunotherapy administered systemically. * Participants must have at least one site of disease measurable in two dimensions by computed tomography (CT). * Age ≥ 18 years. * Adequate bone marrow, liver, and renal functions. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Negative pregnancy test for women of childbearing potential. Exclusion criteria: * Relapse within 100 days of autologous or allogeneic bone marrow transplant. * Prior histone deacetylase (HDAC) inhibitor therapy. * Co-existing active infection or any medical condition likely to interfere with trial procedures. * Severe cardiovascular disease. * Clinically significant central nervous system disorders with altered mental status or psychiatric disorders precluding understanding of the informed consent process and/or completion of the necessary studies. * Active concurrent malignancy (except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix). * Symptomatic or untreated central nervous system (CNS) metastases. * Pregnant or breast-feeding women. * Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.